Investigating the Feasibility and Acceptability of a Technology Delivered Physical Activity (PA) Intervention in Cancer: The IMPETUS Cancer Trial. (IMproving ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2017-2018

ABSTRACT

Participants will take part in a 12 week intervention, with at least one follow up at 24 +/- 2 weeks. Each participant will be provided with support, motivation and professional guidance about improving physical activity (PA) levels and will be given a commercially available PA tracker. The PA tracker will also include a smartphone or web-based application, where participants can upload their exercise performed each day, and keep up to date with their goals using their smartphone or by logging on to their computer. The aim of the study is to find out how useful and effective technology with support from a healthcare professional is in helping cancer survivors to become more physically active. This study will measure objective PA levels of the participants at the start of the study and at the end. The acceptability of using this intervention to promote PA in cancer survivors will also be investigated. Detailed Description The overall aim is to determine the feasibility of a specific PA intervention, combining technology and professional input, in the cancer survivor population. Study Design: A single arm feasibility trial of a PA intervention using technology and behavioural change theories as tools to achieve increased PA. Participants in the study will receive 12 weeks of the intervention. Outcomes will be measured at baseline, 12 weeks and 24 weeks (+/- 2 weeks) post baseline. Patient recruitment: Participants will be recruited from those attending the St. James' Hospital oncology and haematology services. Study personnel will provide further information to these patients and assess them for eligibility. Informed consent will be gained from each participant. Sample size: Proposed sample size is 60 (based on Sim and Lewis, 2012 recommendations) and allowing for 20% drop-out. Intervention: This study will use the commercially available 'Fitbit' wearable technology with its paired smartphone application. PA goals will be prescribed by a qualified, chartered physiotherapist using the American Cancer Society (ACS) guidelines (Doyle et al 2006). Participants will use the Fitbit and its paired application for 12 weeks. The Fitbit device is a tool for motivation and monitoring of PA behaviours in this intervention. This study will also use evidence-based psychological behavioural change theory. Behavioural change techniques include 'self-monitoring of behaviour', 'goal-setting', 'feedback on behaviour' and 'information about health consequences'. Procedures: This study includes time-points at baseline, 12 weeks (Intervention end) and 24 weeks post baseline (+/- 2 weeks (Follow-up). Pre-intervention:Consent and PA measurement - Consent: Study personnel meets potential participants at their outpatient appointment. The agreement of the patient's consultant to exercise has been obtained before the patient information leaflet (PIL) is provided. The researcher explains the study and gives the potential participant a consent form and a patient information leaflet and a verbal explanation of the study. - Initial PA measurement: Participants who consent are given an Actigraph PA monitor which they will be instructed to wear for 7 days to measure their baseline physical activity levels. Participants who wish to consider the study can take the PIL home, post it back, and receive the Actigraph by post. Baseline Session: Participants attend - 1) An educational session, delivered by the lead researcher, a chartered physiotherapist. This is a group information session on PA following cancer treatment. - 2) Educational session to introduce the technological component to the participants and instruct them in use and upload of Fitbit data to allow monitoring by researcher(s). - 3) Measurement of height, weight, BMI and body composition and 6 minute walk test During intervention. (week 1-12) - Participants wear Fitbit and upload data for self-monitoring and monitoring by chartered physiotherapist researcher. - Participants receive scheduled structured telephone calls, giving them feedback on their achievement of goals and reminders about uploading data as follows; 2 calls each week till week 4, 1 call a week between week 4 and 8 and 2 calls, 2 weeks apart between week 8 and week 12. After intervention ends (12 weeks): - Measurement of height, weight, BMI and body composition and 6 minute walk test - Participants wear Actigraph x 7 days 12 weeks after end of intervention: - Measurement of height, weight, BMI and body composition and 6 minute walk test - Participants wear Actigraph x 7 days More... »

URL

https://clinicaltrials.gov/show/NCT03036436

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3177", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Participants will take part in a 12 week intervention, with at least one follow up at 24 +/- 2 weeks. Each participant will be provided with support, motivation and professional guidance about improving physical activity (PA) levels and will be given a commercially available PA tracker. The PA tracker will also include a smartphone or web-based application, where participants can upload their exercise performed each day, and keep up to date with their goals using their smartphone or by logging on to their computer. The aim of the study is to find out how useful and effective technology with support from a healthcare professional is in helping cancer survivors to become more physically active. This study will measure objective PA levels of the participants at the start of the study and at the end. The acceptability of using this intervention to promote PA in cancer survivors will also be investigated.\n\nDetailed Description\nThe overall aim is to determine the feasibility of a specific PA intervention, combining technology and professional input, in the cancer survivor population. Study Design: A single arm feasibility trial of a PA intervention using technology and behavioural change theories as tools to achieve increased PA. Participants in the study will receive 12 weeks of the intervention. Outcomes will be measured at baseline, 12 weeks and 24 weeks (+/- 2 weeks) post baseline. Patient recruitment: Participants will be recruited from those attending the St. James' Hospital oncology and haematology services. Study personnel will provide further information to these patients and assess them for eligibility. Informed consent will be gained from each participant. Sample size: Proposed sample size is 60 (based on Sim and Lewis, 2012 recommendations) and allowing for 20% drop-out. Intervention: This study will use the commercially available 'Fitbit' wearable technology with its paired smartphone application. PA goals will be prescribed by a qualified, chartered physiotherapist using the American Cancer Society (ACS) guidelines (Doyle et al 2006). Participants will use the Fitbit and its paired application for 12 weeks. The Fitbit device is a tool for motivation and monitoring of PA behaviours in this intervention. This study will also use evidence-based psychological behavioural change theory. Behavioural change techniques include 'self-monitoring of behaviour', 'goal-setting', 'feedback on behaviour' and 'information about health consequences'. Procedures: This study includes time-points at baseline, 12 weeks (Intervention end) and 24 weeks post baseline (+/- 2 weeks (Follow-up). Pre-intervention:Consent and PA measurement - Consent: Study personnel meets potential participants at their outpatient appointment. The agreement of the patient's consultant to exercise has been obtained before the patient information leaflet (PIL) is provided. The researcher explains the study and gives the potential participant a consent form and a patient information leaflet and a verbal explanation of the study. - Initial PA measurement: Participants who consent are given an Actigraph PA monitor which they will be instructed to wear for 7 days to measure their baseline physical activity levels. Participants who wish to consider the study can take the PIL home, post it back, and receive the Actigraph by post. Baseline Session: Participants attend - 1) An educational session, delivered by the lead researcher, a chartered physiotherapist. This is a group information session on PA following cancer treatment. - 2) Educational session to introduce the technological component to the participants and instruct them in use and upload of Fitbit data to allow monitoring by researcher(s). - 3) Measurement of height, weight, BMI and body composition and 6 minute walk test During intervention. (week 1-12) - Participants wear Fitbit and upload data for self-monitoring and monitoring by chartered physiotherapist researcher. - Participants receive scheduled structured telephone calls, giving them feedback on their achievement of goals and reminders about uploading data as follows; 2 calls each week till week 4, 1 call a week between week 4 and 8 and 2 calls, 2 weeks apart between week 8 and week 12. After intervention ends (12 weeks): - Measurement of height, weight, BMI and body composition and 6 minute walk test - Participants wear Actigraph x 7 days 12 weeks after end of intervention: - Measurement of height, weight, BMI and body composition and 6 minute walk test - Participants wear Actigraph x 7 days", 
    "endDate": "2018-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03036436", 
    "keywords": [
      "feasibility", 
      "acceptability", 
      "Motor Activity", 
      "intervention", 
      "cancer trial", 
      "exercise", 
      "cancer survivor", 
      "motivation", 
      "professional", 
      "tracker", 
      "smartphones", 
      "web-based application", 
      "upload", 
      "date", 
      "logging", 
      "computer", 
      "effective technology", 
      "Delivery of Health Care", 
      "physical activity level", 
      "start", 
      "overall aim", 
      "physical activity intervention", 
      "technology", 
      "study design", 
      "feasibility trial", 
      "behavioral change", 
      "tool", 
      "increased physical activity", 
      "baseline", 
      "Patient Selection", 
      "hospital", 
      "oncology", 
      "haematology", 
      "study personnel", 
      "patient", 
      "eligibility", 
      "informed consent", 
      "sample size", 
      "Lewis", 
      "recommendation", 
      "drop-out", 
      "smartphone application", 
      "American Cancer Society", 
      "guideline", 
      "Doyle", 
      "physical activity behavior", 
      "behavior", 
      "goal setting", 
      "feedback", 
      "health consequence", 
      "method", 
      "time point", 
      "follow-up", 
      "pre-intervention", 
      "consent", 
      "measurement", 
      "potential participant", 
      "outpatient appointment", 
      "agreement", 
      "consultant", 
      "patient information", 
      "consent form", 
      "explanation", 
      "activity measurement", 
      "actigraph", 
      "educational session", 
      "information session", 
      "cancer treatment", 
      "component", 
      "instruct", 
      "height", 
      "weight", 
      "BMI", 
      "body composition", 
      "upload data", 
      "self-monitoring", 
      "telephone", 
      "achievement", 
      "reminder", 
      "uploading"
    ], 
    "name": "Investigating the Feasibility and Acceptability of a Technology Delivered Physical Activity (PA) Intervention in Cancer: The IMPETUS Cancer Trial. (IMproving Physical Activity and Exercise With Technology Use in Cancer Survivors)", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03036436"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00023.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.8217.c", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.416409.e", 
        "type": "Organization"
      }
    ], 
    "startDate": "2017-01-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1016/j.jclinepi.2011.07.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001197037"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.305.6846.160", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009614393"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/canjclin.56.6.323", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032717896"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1037/0022-006x.51.3.390", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034416378"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12160-013-9486-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045811160", 
          "https://doi.org/10.1007/s12160-013-9486-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076279750", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080102826", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1993.11.3.570", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082809601"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03036436"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03036436'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03036436'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03036436'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03036436'


 

This table displays all metadata directly associated to this object as RDF triples.

124 TRIPLES      16 PREDICATES      104 URIs      89 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03036436 schema:about anzsrc-for:3177
2 schema:description Participants will take part in a 12 week intervention, with at least one follow up at 24 +/- 2 weeks. Each participant will be provided with support, motivation and professional guidance about improving physical activity (PA) levels and will be given a commercially available PA tracker. The PA tracker will also include a smartphone or web-based application, where participants can upload their exercise performed each day, and keep up to date with their goals using their smartphone or by logging on to their computer. The aim of the study is to find out how useful and effective technology with support from a healthcare professional is in helping cancer survivors to become more physically active. This study will measure objective PA levels of the participants at the start of the study and at the end. The acceptability of using this intervention to promote PA in cancer survivors will also be investigated. Detailed Description The overall aim is to determine the feasibility of a specific PA intervention, combining technology and professional input, in the cancer survivor population. Study Design: A single arm feasibility trial of a PA intervention using technology and behavioural change theories as tools to achieve increased PA. Participants in the study will receive 12 weeks of the intervention. Outcomes will be measured at baseline, 12 weeks and 24 weeks (+/- 2 weeks) post baseline. Patient recruitment: Participants will be recruited from those attending the St. James' Hospital oncology and haematology services. Study personnel will provide further information to these patients and assess them for eligibility. Informed consent will be gained from each participant. Sample size: Proposed sample size is 60 (based on Sim and Lewis, 2012 recommendations) and allowing for 20% drop-out. Intervention: This study will use the commercially available 'Fitbit' wearable technology with its paired smartphone application. PA goals will be prescribed by a qualified, chartered physiotherapist using the American Cancer Society (ACS) guidelines (Doyle et al 2006). Participants will use the Fitbit and its paired application for 12 weeks. The Fitbit device is a tool for motivation and monitoring of PA behaviours in this intervention. This study will also use evidence-based psychological behavioural change theory. Behavioural change techniques include 'self-monitoring of behaviour', 'goal-setting', 'feedback on behaviour' and 'information about health consequences'. Procedures: This study includes time-points at baseline, 12 weeks (Intervention end) and 24 weeks post baseline (+/- 2 weeks (Follow-up). Pre-intervention:Consent and PA measurement - Consent: Study personnel meets potential participants at their outpatient appointment. The agreement of the patient's consultant to exercise has been obtained before the patient information leaflet (PIL) is provided. The researcher explains the study and gives the potential participant a consent form and a patient information leaflet and a verbal explanation of the study. - Initial PA measurement: Participants who consent are given an Actigraph PA monitor which they will be instructed to wear for 7 days to measure their baseline physical activity levels. Participants who wish to consider the study can take the PIL home, post it back, and receive the Actigraph by post. Baseline Session: Participants attend - 1) An educational session, delivered by the lead researcher, a chartered physiotherapist. This is a group information session on PA following cancer treatment. - 2) Educational session to introduce the technological component to the participants and instruct them in use and upload of Fitbit data to allow monitoring by researcher(s). - 3) Measurement of height, weight, BMI and body composition and 6 minute walk test During intervention. (week 1-12) - Participants wear Fitbit and upload data for self-monitoring and monitoring by chartered physiotherapist researcher. - Participants receive scheduled structured telephone calls, giving them feedback on their achievement of goals and reminders about uploading data as follows; 2 calls each week till week 4, 1 call a week between week 4 and 8 and 2 calls, 2 weeks apart between week 8 and week 12. After intervention ends (12 weeks): - Measurement of height, weight, BMI and body composition and 6 minute walk test - Participants wear Actigraph x 7 days 12 weeks after end of intervention: - Measurement of height, weight, BMI and body composition and 6 minute walk test - Participants wear Actigraph x 7 days
3 schema:endDate 2018-12-01T00:00:00Z
4 schema:keywords American Cancer Society
5 BMI
6 Delivery of Health Care
7 Doyle
8 Lewis
9 Motor Activity
10 Patient Selection
11 acceptability
12 achievement
13 actigraph
14 activity measurement
15 agreement
16 baseline
17 behavior
18 behavioral change
19 body composition
20 cancer survivor
21 cancer treatment
22 cancer trial
23 component
24 computer
25 consent
26 consent form
27 consultant
28 date
29 drop-out
30 educational session
31 effective technology
32 eligibility
33 exercise
34 explanation
35 feasibility
36 feasibility trial
37 feedback
38 follow-up
39 goal setting
40 guideline
41 haematology
42 health consequence
43 height
44 hospital
45 increased physical activity
46 information session
47 informed consent
48 instruct
49 intervention
50 logging
51 measurement
52 method
53 motivation
54 oncology
55 outpatient appointment
56 overall aim
57 patient
58 patient information
59 physical activity behavior
60 physical activity intervention
61 physical activity level
62 potential participant
63 pre-intervention
64 professional
65 recommendation
66 reminder
67 sample size
68 self-monitoring
69 smartphone application
70 smartphones
71 start
72 study design
73 study personnel
74 technology
75 telephone
76 time point
77 tool
78 tracker
79 upload
80 upload data
81 uploading
82 web-based application
83 weight
84 schema:name Investigating the Feasibility and Acceptability of a Technology Delivered Physical Activity (PA) Intervention in Cancer: The IMPETUS Cancer Trial. (IMproving Physical Activity and Exercise With Technology Use in Cancer Survivors)
85 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03036436
86 schema:sdDatePublished 2019-03-07T15:27
87 schema:sdLicense https://scigraph.springernature.com/explorer/license/
88 schema:sdPublisher N2579340ca1b9402db7deb57bf06f9512
89 schema:sponsor https://www.grid.ac/institutes/grid.416409.e
90 https://www.grid.ac/institutes/grid.8217.c
91 schema:startDate 2017-01-01T00:00:00Z
92 schema:subjectOf sg:pub.10.1007/s12160-013-9486-6
93 https://app.dimensions.ai/details/publication/pub.1076279750
94 https://app.dimensions.ai/details/publication/pub.1080102826
95 https://doi.org/10.1016/j.jclinepi.2011.07.011
96 https://doi.org/10.1037/0022-006x.51.3.390
97 https://doi.org/10.1136/bmj.305.6846.160
98 https://doi.org/10.1200/jco.1993.11.3.570
99 https://doi.org/10.3322/canjclin.56.6.323
100 schema:url https://clinicaltrials.gov/show/NCT03036436
101 sgo:license sg:explorer/license/
102 sgo:sdDataset clinical_trials
103 rdf:type schema:MedicalStudy
104 N2579340ca1b9402db7deb57bf06f9512 schema:name Springer Nature - SN SciGraph project
105 rdf:type schema:Organization
106 anzsrc-for:3177 schema:inDefinedTermSet anzsrc-for:
107 rdf:type schema:DefinedTerm
108 sg:pub.10.1007/s12160-013-9486-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045811160
109 https://doi.org/10.1007/s12160-013-9486-6
110 rdf:type schema:CreativeWork
111 https://app.dimensions.ai/details/publication/pub.1076279750 schema:CreativeWork
112 https://app.dimensions.ai/details/publication/pub.1080102826 schema:CreativeWork
113 https://doi.org/10.1016/j.jclinepi.2011.07.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001197037
114 rdf:type schema:CreativeWork
115 https://doi.org/10.1037/0022-006x.51.3.390 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034416378
116 rdf:type schema:CreativeWork
117 https://doi.org/10.1136/bmj.305.6846.160 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009614393
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1200/jco.1993.11.3.570 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082809601
120 rdf:type schema:CreativeWork
121 https://doi.org/10.3322/canjclin.56.6.323 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032717896
122 rdf:type schema:CreativeWork
123 https://www.grid.ac/institutes/grid.416409.e schema:Organization
124 https://www.grid.ac/institutes/grid.8217.c schema:Organization
 




Preview window. Press ESC to close (or click here)


...